Clinical Trials

Clinical Trial Detail

Return to search results.

Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Complete title: Longitudinal Study of Immune Mediated Disorders after Allogeneic HCT

Research Study Number       2342.00
    
Principal Investigator       Stephanie Lee, MD, MPH
    
Phase       NA

Look up trial at NIH

Research Study Description

Purpose:

The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD) after stem cell transplant.

Eligibility Criteria (must meet the following to participate in this study)

Genders Eligible for Study: Both

- Planned or completed first allogeneic stem cell transplant (any conditioning regimen, graft source, donor type and GVHD prophylaxis regimen)

- Signed, informed consent and, if applicable, child assent

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

- Inability to comply with study procedures

- Anticipated survival less than 6 months due to co-morbid disease

- Autoimmune disorder or inherited immunodeficiency before HCT

- Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of HCT or at the time of enrollment (e.g., > 5% blasts for leukemia; poorly responsive lymphoma)

Other exclusion criteria may apply.



Research Study Number       2342.00
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Systemic Sclerosis; Chronic Graft Versus Host Disease (cGVHD); Bronchioloalveolar Carcinoma (BAC)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.